MPLT
MapLight Therapeutics, Inc. NASDAQ Listed Oct 24, 2025$28.82
-1.34%
vs $29.21
Mkt Cap $22.7M
52w Low $12.24
78.8% of range
52w High $33.28
50d MA $28.92
200d MA $21.11
P/E (TTM)
-7.9x
EV/EBITDA
—
P/B
2.8x
Debt/Equity
0.0x
ROE
-35.2%
P/FCF
-9.2x
RSI (14)
48.70
ATR (14)
$2.49
Beta
-2.79
50d MA
$28.92
200d MA
$21.11
Avg Volume
320.1K
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
800 Chesapeake Drive · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | BMO | -1.05 | -2.47 | -135.2% | 19.23 | +0.4% | -3.5% | +0.9% | +8.7% | +2.5% | +1.6% | — |
| Dec 4, 2025 | BMO | -1.72 | -37.18 | -2061.6% | 18.34 | -1.3% | +0.8% | -0.2% | +2.2% | +8.3% | -1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27 | UBS | Initiates | Buy | $48 | $29.46 | $29.99 | +1.8% | +0.3% | +0.8% | -1.6% | +1.5% | -8.1% |
| May 21 | Craig Hallum | Initiates | Buy | $43 | $27.81 | $28.11 | +1.1% | +5.3% | -1.8% | +2.5% | +0.3% | +0.8% |
| May 4 | H.C. Wainwright | Initiates | Buy | $45 | $30.70 | $30.55 | -0.5% | -6.8% | -2.4% | +4.0% | +0.6% | -6.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 198 | $28.15 | $6K | 1,394,094 | +2.19% | +2.47% |
| May 18, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 118,037 | $27.19 | $3.2M | 1,394,292 | +2.19% | +2.47% |
| May 11, 2026 | Hanson Kristopher | General Counsel | Sell | 5,808 | $30.56 | $177K | 162,331 | +0.70% | -7.76% |
| May 11, 2026 | Hanson Kristopher | General Counsel | Sell | 6,979 | $30.04 | $210K | 168,139 | +0.70% | -7.76% |
| May 11, 2026 | Hanson Kristopher | General Counsel | Sell | 846 | $28.70 | $24K | 175,118 | +0.70% | -7.76% |
| May 11, 2026 | Hanson Kristopher | General Counsel | Sell | 284 | $27.61 | $8K | 175,964 | +0.70% | -7.76% |
| May 11, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 5,890 | $30.56 | $180K | 1,512,329 | +0.70% | -7.76% |
| May 11, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 6,871 | $30.04 | $206K | 1,518,219 | +0.70% | -7.76% |
| May 11, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 877 | $28.70 | $25K | 1,525,090 | +0.70% | -7.76% |
| May 11, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 342 | $27.57 | $9K | 1,525,967 | +0.70% | -7.76% |
| May 8, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 3,205 | $29.20 | $94K | 1,526,309 | +0.70% | -7.76% |
| May 8, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 1,582 | $28.56 | $45K | 1,529,514 | +0.70% | -7.76% |
| May 8, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 29,624 | $27.48 | $814K | 1,531,096 | +0.70% | -7.76% |
| May 7, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 721 | $28.28 | $20K | 242,729 | +0.70% | -7.76% |
| May 7, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 117 | $29.10 | $3K | 346,059 | +0.70% | -7.76% |
| May 7, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 4,321 | $28.52 | $123K | 346,176 | +0.70% | -7.76% |
| May 7, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 5,220 | $29.15 | $152K | 1,560,720 | +0.70% | -7.76% |
| May 7, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 14,880 | $28.47 | $424K | 1,565,940 | +0.70% | -7.76% |
| May 6, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 15,900 | $29.13 | $463K | 350,497 | +0.55% | +1.22% |
| May 6, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 8,152 | $28.04 | $229K | 366,397 | +0.55% | +1.22% |
| May 6, 2026 | Setia Vishwas | Chief Financial Officer | Sell | 2,068 | $29.07 | $60K | 356,256 | +0.55% | +1.22% |
| May 6, 2026 | Setia Vishwas | Chief Financial Officer | Sell | 8,496 | $28.04 | $238K | 358,324 | +0.55% | +1.22% |
| May 6, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 15,603 | $29.13 | $455K | 1,580,820 | +0.55% | +1.22% |
| May 6, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 8,098 | $28.04 | $227K | 1,596,423 | +0.55% | +1.22% |
| May 6, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 16,421 | $29.13 | $478K | 243,450 | +0.55% | +1.22% |
| May 6, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 8,390 | $28.04 | $235K | 259,871 | +0.55% | +1.22% |
| May 5, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 931 | $29.00 | $27K | 374,549 | +0.55% | +1.22% |
| May 5, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 9,645 | $28.12 | $271K | 375,480 | +0.55% | +1.22% |
| May 5, 2026 | Setia Vishwas | Chief Financial Officer | Sell | 968 | $29.00 | $28K | 366,820 | +0.55% | +1.22% |
| May 5, 2026 | Setia Vishwas | Chief Financial Officer | Sell | 9,935 | $28.12 | $279K | 367,788 | +0.55% | +1.22% |
8-K · 2.02
!! High
MapLight Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K
MapLight Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful investment analysis as the filing summary lacks substantive business information regarding MapLight Therapeutics' material events or developments.
Apr 29
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
# Analysis: FTRK, MPLT
Companies disclosed material information via press release and presentation on March 26, 2026, signaling potential earnings catalyst or strategic announcement—investors should review exhibits for specifics on forward guidance or operational developments affecting valuations.
Mar 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blue Owl Capital Holdings Lp | 1,005,929 | $20M | Added | Mar 2026 |
| 2 | Nan Fung Group Holdings Ltd | 971,253 | $20M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 719,820 | $15M | New | Mar 2026 |
| 4 | Velan Capital Investment Management Lp | 492,893 | $10M | Reduced | Mar 2026 |
| 5 | Adar1 Capital Management, Llc | 374,909 | $8M | New | Mar 2026 |
| 6 | Bnp Paribas Asset Management Holding S.a. | 267,746 | $5M | Added | Mar 2026 |
| 7 | Ubs Group Ag | 236,512 | $5M | Added | Mar 2026 |
| 8 | Fmr Llc | 204,501 | $4M | Added | Mar 2026 |
| 9 | Superstring Capital Management Lp | 192,139 | $4M | New | Mar 2026 |
| 10 | Northern Trust Corp | 146,172 | $3M | Added | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 112,604 | $2M | New | Mar 2026 |
| 12 | Stempoint Capital Lp | 100,000 | $2M | New | Mar 2026 |
| 13 | Seven Grand Managers, Llc | 100,000 | $2M | New | Dec 2025 |
| 14 | Janus Henderson Group Plc | 54,752 | $1M | New | Mar 2026 |
| 15 | Morgan Stanley | 46,444 | $816K | New | Dec 2025 |
| 16 | Bank Of New York Mellon Corp | 39,465 | $802K | Added | Mar 2026 |
| 17 | Bnp Paribas Financial Markets | 37,301 | $758K | Added | Mar 2026 |
| 18 | Tudor Investment Corp | 36,740 | $747K | New | Mar 2026 |
| 19 | Walleye Capital Llc | 23,144 | $471K | Reduced | Mar 2026 |
| 20 | Nuveen, Llc | 23,089 | $469K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$22.7M
Enterprise Value
$963.7M
P/E (TTM)
-7.87x
Forward P/E
—
PEG Ratio
-0.05x
P/B
2.77x
P/S
—
P/FCF
-9.15x
EV/EBITDA
—
Shares Out
44.0M
Financials (TTM)
Revenue
$0
Net Income
-$161.2M
EBITDA
-$168.5M
Free Cash Flow
-$138.6M
Op Cash Flow
-$138.1M
EPS Basic
$-3.66
EPS Diluted
$-3.66
EPS Forward
$-4.28
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$479.5M
Total Liab.
$21.1M
Total Equity
$458.4M
Cash
$305.1M
LT Debt
$0
Book Value/Sh
$10.41
Debt/Equity
0.01x
Current Ratio
20.01
Quick Ratio
20.01
Returns & Growth
ROE
-35.2%
ROA
-33.6%
ROIC
-36.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
-95.7%
Price Returns
2W
+0.1%
1M
-8.0%
3M
+69.7%
6M
+115.0%
12M
+59.8%
Technicals
52W High
$33.28
52W Low
$12.24
50d MA
$28.92
200d MA
$21.11
RSI (14)
48.70
ATR (14)
$2.49
Beta
-2.79
Avg Volume
320K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$31.00
High
$34.00
Low
$28.00
Median
$31.00
Data updated apr 26, 2026 1:05pm
· Source: financialmodelingprep.com